Co- and multipathologies need serious consideration for understanding Parkinson's disease pathogenesis and designing novel experimental therapeutic strategies
Sep 2026· Journal of Parkinson's Disease· 0 citations· 40 references
Medicine
TL;DR
Investigation of anti-α -synuclein immunotherapy as a potential disease-modifying strategy for PD found no evidence of delay in motor progression and exploratory studies suggested potential clinical activity.
Abstract
Parkinson ’ s disease (PD) is pathologically de fi ned by the presence of aggregated α -synuclein in the form of Lewy bodies and Lewy neurites. 1 – 4 Considerable interest has focused on anti-α -synuclein immunotherapy as a potential disease-modifying strategy for PD, but initial phase 2a clinical trials examining this approach did not meet their primary endpoint. Most recently, the phase 2b PADOVA trial of prasinezumab, published in The Lancet Neurology , also did not meet its primary endpoint, although a non-signi fi cant delay in motor progression and prespeci fi ed exploratory fi ndings suggested potential clinical activity. 5 – 7
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, and its rising incidence poses a growing burden on productivity and healthcare systems, particularly in the context of global population aging. Despite substantial advances in research, the pathogenesis of PD remains incompletely understood,...
Rong Hu, Ya-Ru Song, Ting Y. Liu et al.· Frontiers in Immunology· 0 citations
Parkinson's disease (PD) is the second most common neurodegenerative disorder and its prevalence continues to rise with population aging. Its cardinal motor features arise from the loss of dopaminergic neurons in the substantia nigra, accompanied by intraneuronal α-synuclein aggregates known as Lewy bodies. Neuropathol...
Yi-Cheng Tai, Chin-Hsien Lin· Journal of Movement Disorder...· 0 citations
A variety of evidence now supports two interrelated hypotheses concerning Alzheimer’s disease (AD) neurofibrillary pathology (NFT), its prevention and treatment. The first hypothesis: the receptor type protein tyrosine phosphatase D (PTPRD) plays a key role in AD NFT pathogenesis by modulating activities of neuronal gl...
George R. Uhl, Joungil Choi, B. Kannan et al.· Biomedicines· 0 citations
The urgent need for reliable biomarkers, early diagnosis, and multidisciplinary disease-modifying strategies for future therapeutic interventions is highlighted, with particular emphasis on challenges associated with bench-to-bedside translation.
Jeewanjot Singh, Subhi Sharma, Prabhjot Singh et al.· 0 citations
Discussing the effectiveness of the recent therapy for Huntington's illness is the main ambition in this regard, and a variety of treatments are accessible to lessen the symptoms of Hunti ngton's disorder, and efficient solutions for its chorea.
We are in an era in which increasing numbers of potentially disease-modifying treatments for Parkinson's disease are being tested in clinical development. Current definitions of disease modification have inherent limitations; hence there is a need to establish a clear, unified definition. This unified definition of dis...
A. Antonini, Robert E. Gross, María Lucia De León et al.· Journal of Parkinson's Disea...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
